Literature DB >> 23145363

(18)F-DOPA PET with and without MRI fusion, a receiver operator characteristics comparison.

Aaron F Struck1, Lance T Hall, Joanna E Kusmirek, Catherine L Gallagher, John M Floberg, Christine J Jaskowiak, Scott B Perlman.   

Abstract

This study is a retrospective analysis of the diagnostic accuracy of FDOPA PET with MRI fusion to FDOPA PET without MRI fusion. Clinical FDOPA PET scans obtained between 2000 and 2008 at the University of Wisconsin Hospital and Clinics were assessed using measures derived from regions of interest (ROI) generated with fused MRI (fused group) and again with ROIs derived solely from PET data (non-fused groups). The ROIs were used to calculate ratios (Striatum/Occipital cortex, Striatum/Cerebellum) pertinent to Parkinson's disease (PD) pathology. The clinical records were assessed for demographic data, follow-up length, and diagnosis. Receiver Operator Characteristics with area under the curve (AUC) measures were calculated and compared using confidence intervals and hypothesis testing. 27 patients had FDOPA PET with median clinical follow-up of 4 years. Of these, 17 patients had FDOPA PET with a fusible MR image. Seven of the 27 had a non-PD movement disorder. AUCs for the ratio measures ranged from 0.97-1.0 (fused), 0.73-0.83 (non-fused), and 0.63-0.82 (matched non-fused). The fused images had improved accuracy compared to the matched non-fused and all non-fused groups for the striatum to occipital group (p=0.04, p=0.03), while the striatum to cerebellum ratio had improvement over the non-fused all group (p=0.041). MR fusion to FDOPA PET improves the accuracy of at least some measures (Striatum/Occiput, Striatum/Cerebellum) in the diagnosis of PD.

Entities:  

Keywords:  18F-Fluorodopa; Parkinson’s; image fusion; positron emission tomography; receiver operator characteristics

Year:  2012        PMID: 23145363      PMCID: PMC3484423     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  20 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's disease.

Authors:  Xiao-Bo Pan; Thomas G Wright; F Joel Leong; Robert A McLaughlin; Jérôme M Declerck; Daniel H S Silverman
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

3.  Statistical comparison of two ROC-curve estimates obtained from partially-paired datasets.

Authors:  C E Metz; B A Herman; C A Roe
Journal:  Med Decis Making       Date:  1998 Jan-Mar       Impact factor: 2.583

4.  Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.

Authors:  Pekka Jokinen; Hans Helenius; Elina Rauhala; Anna Brück; Olli Eskola; Juha O Rinne
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

5.  Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

Authors:  B J Snow; I Tooyama; E G McGeer; T Yamada; D B Calne; H Takahashi; H Kimura
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

6.  Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.

Authors:  B D Pate; T Kawamata; T Yamada; E G McGeer; K A Hewitt; B J Snow; T J Ruth; D B Calne
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

7.  Striatal dopamine distribution in parkinsonian patients during life.

Authors:  C Nahmias; E S Garnett; G Firnau; A Lang
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

8.  Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study.

Authors:  Robert Y Moore; Alan L Whone; David J Brooks
Journal:  Neurobiol Dis       Date:  2007-09-26       Impact factor: 5.996

9.  In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study.

Authors:  Nicola Pavese; Robert Y Moore; Christoph Scherfler; Naheed L Khan; Gary Hotton; Niall P Quinn; Kailash P Bhatia; Nicholas W Wood; David J Brooks; Andrew J Lees; Paola Piccini
Journal:  Exp Neurol       Date:  2010-01-04       Impact factor: 5.330

10.  Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.

Authors:  A Antonini; P Vontobel; M Psylla; I Günther; P R Maguire; J Missimer; K L Leenders
Journal:  Arch Neurol       Date:  1995-12
View more
  2 in total

1.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

2.  The sensitivity and specificity of F-DOPA PET in a movement disorder clinic.

Authors:  Nevein Ibrahim; Joanna Kusmirek; Aaron F Struck; John M Floberg; Scott B Perlman; Catherine Gallagher; Lance T Hall
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.